Clinical trials
Immunosuppression clinical trials
Below are recruiting immunosuppression clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06346665Recruiting
Transplant infection study for organ and stem cell recipients
This trial follows people who have had a recent organ or stem cell transplant to learn more about infections and how they can be prevented. You may be asked to provide samples and information over time.
MünchenAges Any age - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT06268769RecruitingPhase 4
Comparing two tacrolimus drugs in kidney transplant patients
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
AachenAges 18 years+ - NCT07775235Recruiting
Treatment outcomes for muscle inflammation with rapid lung disease
This study looks at how well treatments work for people with muscle inflammation (myositis) that causes a fast-progressing lung condition. It may help doctors find better ways to manage this serious combination.
SingaporeAges 21 years+ - NCT04521790Recruiting
Biopsy-guided treatment for suspected inflammation of the heart
This study looks at people 18 and older with suspected myocarditis (inflammation of the heart). It uses an inner-heart biopsy and tailored treatment based on the likely cause to improve diagnosis and care, especially for people with different heart rhythm or non-rhythm symptoms.
Milan, MilanoAges 18 years+ - NCT07739914RecruitingPhase 3
Switching anti-rejection medicine after a liver transplant
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Heidelberg, Baden-WurttembergAges 18–80 - NCT07680816Recruiting
Study of gamma delta T cells in critically ill patients
This study looks at a type of immune cell called gamma delta T cells in patients who are very sick in the ICU, including those with and without sepsis. The goal is to understand how these cells work differently in these patients, which could help find better treatments.
Wuhan, Outside of the USAges 18–80 - NCT06463119Recruiting
Vaccine response registry for immune-weakened patients
This study creates a registry to track how people with weakened immune systems respond to vaccines. It helps doctors better understand which vaccines work best for patients like you.
GenevaAges Any age - NCT06059989RecruitingPhase 3
Testing a new form of infliximab for Crohn's disease
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Amsterdam, North HollandAges 18–80 - NCT07572071RecruitingPhase 1
Cell transplant study for moderate Parkinson's disease
This trial tests whether transplanting specially grown cells (DopaCell) into the brain can safely help people with moderate Parkinson's disease whose symptoms aren't well controlled by medication. The cells are intended to produce dopamine, the chemical that Parkinson's affects.
ShirazAges 30–70 - NCT07572383RecruitingPhase 2
Imaging Study of Immunosuppression for Progressive Lung Fibrosis
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
Boston, MassachusettsAges 18–80 - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
San Francisco, CaliforniaAges 3–13 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Anniston, AlabamaAges 18–70 - NCT06821919Recruiting
Diabetes and immune drugs in kidney disease study
This study looks at how diabetes treatments and immune-suppressing drugs affect a process called NETosis, which involves immune cells forming traps. It may help find better ways to treat kidney disease in people with diabetes or immune-related kidney problems.
NahariyaAges 18 years+ - NCT06824714Recruiting
Predicting blood vessel damage in large vessel vasculitis
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
Nanjing, JiangsuAges 18 years+ - NCT06873100RecruitingPhase 1/Phase 2
Upadacitinib for relapsing polychondritis
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT06874257Recruiting
Study of IDO1 inhibitor and PD-1 blocker for AML
This trial tests a combination of two drugs (an IDO1 inhibitor and a PD-1 blocker) given with standard chemotherapy (azacitidine and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if this approach helps the immune system fight the leukemia better.
BolognaAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
La Jolla, CaliforniaAges 16 years+ - NCT05621837Recruiting
Biomarker study to guide treatment for several advanced cancers
This study measures how strongly your immune system is being suppressed and uses that information to help personalize cancer treatment. It mainly looks at people with certain advanced cancers and needs tumor tissue and follow-up to check possible immune-related markers.
MilanAges 18–90 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunosuppression?
- Yes. Clin2 currently lists 90 recruiting immunosuppression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunosuppression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunosuppression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.